Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.

Related Articles

Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.

Oncology (Williston Park). 2018 02 15;32(2):e11-e19

Authors: Lukas RV, Gondi V, Stupp R, Raizer JJ

Abstract
Primary central nervous system (CNS) lymphoma, a rare CNS neoplasm associated with high mortality, is responsive to therapeutic interventions. In Part 1 of our two-part coverage of this entity, we provided an overview of the epidemiology of primary CNS lymphoma, followed by a discussion of the diagnostic and staging evaluation, and a review of current prognostication systems. In Part 2, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation. With respect to systemic therapies, we provide details of a variety of regimens built around a backbone of high-dose methotrexate. Future directions for the treatment of primary CNS lymphoma are reviewed as well. These include optimization of consolidation regimens and the pursuit of novel agents.

PMID: 29492949 [PubMed - in process]

http://ift.tt/2HWDh35